HeartSciences (HSCS) Income from Continuing Operations (2021 - 2026)
HeartSciences (HSCS) posted quarterly Income from Continuing Operations of 2764715.0 for Q2 2026, down 31.57% year-on-year from 4040487.33 in Q2 2025, and down 17.5% on a QoQ basis from 2352937.0 in Q4 2025.
HeartSciences (HSCS) Income from Continuing Operations (2021 - 2026) Analysis & Trends
HeartSciences (HSCS) has reported Income from Continuing Operations for 6 consecutive years, with 2764715.0 the latest figure, recorded in Q2 2026.
- Quarterly Income from Continuing Operations fell 31.57% year-over-year to 2764715.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 24554686.0 (up 51.66% YoY) and the FY2026 annual result came in at 25765152.0, down 10.19% from the prior year.
- Income from Continuing Operations retreated to 2764715.0 in Q2 2026 per HSCS's latest filing, from 2352937.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for HSCS reached as high as 1239354.0 in Q1 2022 and fell as low as 17335783.0 in Q3 2025.
- A 5-year average of 9323960.76 and a median of 12433010.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 1476.03% — and 2025, when it soared 85.34%.
- Year by year, Income from Continuing Operations stood at 12542933.0 in 2022, then dropped by 11.23% to 13951559.0 in 2023, then retreated by 15.02% to 16047179.0 in 2024, then surged by 85.34% to 2352937.0 in 2025, then slipped by 17.5% to 2764715.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2764715.0, 2352937.0, and 17335783.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | HeartSciences | 2.29 Mn | -1.11 Mn | - | -2.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.76 Mn |
| Oct 31, 2025 | -2.35 Mn |
| Jul 31, 2025 | -17.34 Mn |
| Apr 30, 2025 | -2.10 Mn |
| Jan 31, 2025 | -16.96 Mn |
| Oct 31, 2024 | -16.05 Mn |
| Jul 31, 2024 | -15.68 Mn |
| Apr 30, 2024 | -1.90 Mn |
| Jan 31, 2024 | -14.30 Mn |
| Oct 31, 2023 | -13.95 Mn |
| Jul 31, 2023 | -13.35 Mn |
| Apr 30, 2023 | -1.63 Mn |
| Jan 31, 2023 | -12.43 Mn |
| Oct 31, 2022 | -12.54 Mn |
| Jul 31, 2022 | -11.85 Mn |
| Apr 30, 2022 | -2.05 Mn |
| Jan 31, 2022 | -1.24 Mn |
| Oct 31, 2021 | -1.03 Mn |
| Jul 31, 2021 | -752,051.00 |